Gene Transfer to Liver Cancer Cells of B7-1 Plus Interleukin 12 Changes Immunoeffector Mechanisms and Suppresses Helper T Cell Type 1 Cytokine Production Induced by Interleukin 12 Alone
- 1 January 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (1), 127-138
- https://doi.org/10.1089/10430340050016210
Abstract
To investigate the cooperative effect of B7-1 and IL-12 in the induction of antitumor activity, we have developed retroviral vectors encoding human B7-1, murine IL-12, or both B7-1 and IL-12 coordinately. Murine transformed liver cells (BNL) were engineered to stably express B7-1, IL-12, or both by infection with corresponding retroviruses. No tumor was observed in 20, 75, and 95% of mice receiving, respectively, B7-1-, IL-12-, and B7-1/IL-12-modified tumor cells after 250 days of inoculation. In contrast, injection of parental BNL or BNL/Neo cells resulted in lethal tumor progression in all mice. Protection against rechallenge with parental tumor cells was observed only in mice who had rejected BNL/IL-12, but not in animals that rejected BNL/B7-1 or BNL/B7-1-IL-12. Growth of parental tumor cells was significantly delayed by simultaneous injection in a distant site of irradiated tumor cells engineered to express IL-12 or both B7-1 and IL-12 but not B7-1 alone. BNL/B7-1 and BNL/B7-1-IL-12 showed similar efficacy in these experiments. Antitumor immunity induced by B7, with or without IL-12, was found to depend mainly on CD4+ T cells with a minor contribution of a non-T cell mechanism; whereas the effect of IL-12 was dependent on CD8+ T cells and on nonT cell effectors. Immunization of mice with IL-12-modified BNL cells induced secretion of a Th1 pattern of cytokines while immunization with cells expressing both IL-12 and B7-1 resulted in inhibition of IFN-gamma production. Immunization with BNL/B7-1-IL-12 cells in the presence of anti-human B7-1 MAb resulted in restoration of IFN-gamma production to the levels found in animals injected with BNL/IL-12 cells. To summarize, in our model coexpression of B7-1 and IL-12 in tumor cells does not result in improved antitumoral activity as compared with expression of IL-12 alone. This may be related to the fact that B7-1 changes the mechanisms of antitumor immunity and inhibits IFN-gamma production induced by IL-12 in vivo.Keywords
This publication has 32 references indexed in Scilit:
- Enhanced Immunogenicity of B Cell Lymphoma Genetically Engineered to Express Both B7-1 and Interleukin-12Human Gene Therapy, 1997
- Cytokines, tumour-cell death and immunogenicity: a question of choiceImmunology Today, 1997
- Cellular and Molecular Mechanisms Underlying IL-12-Induced Tumor RegressionAnnals of the New York Academy of Sciences, 1996
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapyImmunology Today, 1996
- Interleukin-12 an integral cytokine in the immune responseLife Sciences, 1996
- Cytokines and gene therapyImmunology Today, 1995
- T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.The Journal of Experimental Medicine, 1994
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993